ArticleClinical & experimental metastasis2005
MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer.
Article in Clinical & experimental metastasis, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis.Medicine · 2019Pooled it
- Multiple roles and mechanisms of MUC6 in cancer (Review).International journal of molecular medicine · 2025Review
- E2F4 Promotes Malignant Behaviors of Prostate Cancer Through Activating MUC1 Expression Transcriptionally.Asia-Pacific journal of clinical oncology · 2025Article
- MUC1 expression is associated with ST3GAL2 and negatively correlated with the androgen receptor in castration-resistant prostate cancer.Glycoconjugate journal · 2024Article
- Network and structural analysis of quail mucins with expression pattern of mucin 1 and mucin 4 in the intestines of the Iraqi common quail (Veterinary world · 2024Article
- Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer.Cancer letters · 2023Review
- Management of Primary Female Urethral Adenocarcinoma: Two Rare Case Reports and Literature Review.Medicina (Kaunas, Lithuania) · 2023Review
- Measuring the multifaceted roles of mucin-domain glycoproteins in cancer.Advances in cancer research · 2023Review
- Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.Cancers · 2022Review
- Review
- Glycosylation Changes in Prostate Cancer Progression.Frontiers in oncology · 2021Review
- Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer.Molecular medicine reports · 2020Article
- Claudin-6 is down-regulated in gastric cancer and its potential pathway.Cancer biomarkers : section A of Disease markers · 2020Article
- Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.Pathology oncology research : POR · 2019Review
- Untouchable genes in the human genome: Identifying ideal targets for cancer treatment.Cancer genetics · 2019Article
- Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2019Review
- Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo.BMC cancer · 2018Article
- Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.Molecular oncology · 2018Article
- The Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in Human.Microorganisms · 2018Review
- Prognostic Value of MUC2 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular changes are vital for the development of prognostic markers and therapeutic modalities of prostate cancer (CaP). There is growing interest in mucins as treatment targets in human malignancies, including CaP. The role of their expression in the progression of CaP is however unclear. We examined the expressions MUC1, MUC2, MUC4, MUC5AC and MUC6 in CaP tissues using tissue microarrays (TMAs) to look for tumor-associated antigens (TAAs) for targeted therapy. In this study, 120 paraffin-embedded specimens were selected from patients who underwent radical retro-pubic prostatectomy (RRP) or trans-urethral-resection of the prostate (TURP) for primary, untreated CaP and 10 matched lymph node metastases. A series of MUC monoclonal antibodies (mAbs) was used on TMAs by standard immunohistochemistry. Our results indicate that the over-expression of MUC1 was detected in 58% of primary CaP tissues and 90% of lymph node metastases but not in normal prostate or benign tissues, while the expression of MUC2, MUC4, MUC5AC and MUC6 was found to be negative in both normal and cancer tissues. Of the MUC1 positive tumors 86% were Gleason grade 7 or higher. Over-expression of MUC1 was found in late stage CaP while MUC2, 4, 5AC and 6 were negative in CaP. MUC1 is a TAA that is highly related to tumor progression in CaP patients. This antigen is ideal for targeted therapy to control micrometastases and hormone refractory disease but additional studies are necessary to assess its usefulness in patient biopsies and CaP bone metastases before clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.